CN102861067A - Application of Houttuynoid E in anti-helicobacter pylori (Hp) medicine - Google Patents
Application of Houttuynoid E in anti-helicobacter pylori (Hp) medicine Download PDFInfo
- Publication number
- CN102861067A CN102861067A CN2012104184062A CN201210418406A CN102861067A CN 102861067 A CN102861067 A CN 102861067A CN 2012104184062 A CN2012104184062 A CN 2012104184062A CN 201210418406 A CN201210418406 A CN 201210418406A CN 102861067 A CN102861067 A CN 102861067A
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- helicobacter pylori
- preparation
- ulcer
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 229940037467 helicobacter pylori Drugs 0.000 title claims description 21
- VCNWTZPWIVDHGN-SLBJRTIWSA-N 2-[4,5-dihydroxy-2-(2-oxoundecyl)phenyl]-5,7-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound CCCCCCCCCC(=O)CC1=CC(O)=C(O)C=C1C1=C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 VCNWTZPWIVDHGN-SLBJRTIWSA-N 0.000 title abstract description 46
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 229930190556 houttuynoid Natural products 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 abstract description 14
- 208000007882 Gastritis Diseases 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 7
- 208000023652 chronic gastritis Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 208000000718 duodenal ulcer Diseases 0.000 abstract description 4
- 208000025865 Ulcer Diseases 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 231100000397 ulcer Toxicity 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 241000590002 Helicobacter pylori Species 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 208000009889 Herpes Simplex Diseases 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000002814 agar dilution Methods 0.000 description 4
- 230000003602 anti-herpes Effects 0.000 description 4
- 240000000691 Houttuynia cordata Species 0.000 description 3
- 235000013719 Houttuynia cordata Nutrition 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010019375 Helicobacter infections Diseases 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 241001661641 Verrucosa Species 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
An in vitro activity experiment shows that Houttuynoid E has very strong anti-Hp activity. Houttuynoid E can be utilized to treat diseases, such as acute gastritis, chronic gastritis, gastrohelcosis ulcer and duodenal ulcer and applied to preparation of the medicines for treating acute gastritis, chronic gastritis, gastrohelcosis ulcer and duodenal ulcer. Application of Houttuynoid E in preparation of an anti-Hp medicine provided by the invention is disclosed firstly. The skeleton type belongs to new skeleton type, and the inhibitory activity of Houttuynoid E on Hp is unexpectedly strong; and the probability that any revelation is provided by other compounds does not existe, Houttuynoid E has the excellent substantive features, and Houttuynoid E obviously has a remarkable progress when being used for preventing and treating Hp infection.
Description
Technical field
The invention belongs to biological pharmacy technical field, relate in particular to the application of Houttuynoid E in the preparation Anti-helicobacter pylori drugs.
Background technology
Helicobacter pylori (Helicobacter pylori, Hp) is a kind of Gram-negative spiral bacteria.Studies show that, helicobacter pylori is the main pathogenesis of acute and chronic gastritis and Stomach duodenum ulcer, and may be relevant with the morbidity of gastric cancer stomach function regulating mucosa-associated lymphoid tissue (MALT) malignant lymphoma.Recently, World Health Organization (WHO) is classified as I class carcinogen with Hp, and it plays a leading role in the gastric cancer development.The scheme that at present popular treatment Hp infects is to take simultaneously the triple therapy that proton pump inhibitor (PPI) adds two kinds of antibiotic (clarithromycin, amoxicillin, tetracycline, metronidazole etc. select two kinds).The main factor that affects triple therapy is considered to Hp to the drug resistance of antibacterial; Another serious problems are that proton pump inhibitor can bring out dyspepsia, and a large amount of antibacterial then cause the serious destruction of flora in the digestive tract.Therefore, seek the active kind new medicine thing of efficient, safe anti-Hp and become an important and urgent task.
The compound H outtuynoid E that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid E that the present invention relates in preparation treatment Anti-helicobacter pylori drugs, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for helicobacter pylori, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously helicobacter pylori infections obviously has significant progress.
Summary of the invention
The objective of the invention is to study the application of Houttuynoid E in Anti-helicobacter pylori drugs.
Described compound H outtuynoid E structure is shown in formula I:
The experiment in vitro of Houttuynoid E shows, Houttuynoid E has very strong anti Helicobacter pylori activity, and paper disk method shows that its antibacterial circle diameter is 19 mm (ATCC43504).Show that with agar dilution it can suppress the growth of 5 random clinical strains (Hp001, Hp003, Hp004, Hp018 and Hp036) and 1 reference culture (ATCC43504) fully, minimal inhibitory concentration (MIC) is 1.0 μ g/ml.Make positive control with the ampicillin, it is 2.0 μ g/ml to the Cmin (MIC) that 6 strains test bacterium suppresses fully.
This result of study shows, the energy force rate ampicillin of the inhibition helicobacter pylori activity of Houttuynoid E is strong, explanation for the diseases such as the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer, Houttuynoid E is the chemical compound of a great exploitation potential for its.It can be directly used in the treatment of corresponding disease and the preparation of related drugs.
The purposes of the Houttuynoid E that the present invention relates in preparation treatment Anti-helicobacter pylori drugs belongs to open first, because framework types belongs to brand-new framework types, and it suppresses active unexpectedly strong for helicobacter pylori, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously helicobacter pylori infections obviously has significant progress.
The specific embodiment
The preparation method of compound H outtuynoid E involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid E tablet involved in the present invention:
Get 20 and digest compound Houttuynoid E, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid E capsule involved in the present invention:
Get 20 and digest compound Houttuynoid E, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
The pharmacological evaluation of Houttuynoid E
1) strains tested
Helicobacter pylori (Helicobacter pylori, Hp) reference culture ATCC 43504 is purchased from U.S.'s strain and preserves center (American Type Culture Collection, ATCC).15 strain Hp clinical strains are picked up from Jiangsu Prov. People's Hospital Gastroenterology dept., clinical laboratory of Jiangsu TCM Hospital and Nanjing Children's Hospital Dndoscope Laboratory and are accepted gastroscopic patient; In continuous gastroscopy to the patient of peptic ulcer, duodenal bulbar inflammation or gastritis verrucosa, be defined as the Hp positive through the RUT experiment first, get again antral gastric mucosa 1-2 piece, be inoculated in after the chopping and contain 8% horse serum, trimethoprim (trimethropin, TMP) in the Columbia selectivity agar culture medium of 1.25 g/L, polymyxin (polymyxin) B2500 U/L, vancomycin (vancomycin) 10 mg/L, in 37 ° of C (5% O under little oxygen environment
2, 10% CO
2With 85% N
2) cultivated 72 hours.Collect antibacterial, through the smear Gram’s staining, after oxidase, catalase and urease are accredited as the positive, the pure culture of going down to posterity, obtained strains is as experimental strain.
2) strain culturing
We adopt little aerobic bag (available from Shanghai Medical Univ) to carry out the strain culturing of HP, and it can produce the needed little aerobic environment of Hp by chemical reaction.
3) biological activity determination
Adopt paper disk method (Microbiological paper method) to measure chemical compound to the inhibitory action of helicobacter pylori, measure the minimum inhibitory concentration (minimal inhibitory concentration, MIC) of test sample with agar dilution.
I. paper disk method experiment
(A) prepare culture medium with the Columbia culture medium for preparing behind high pressure steam sterilization, be cooled to 50-60 ℃, add 8% horse serum or Sheep Blood, mixing is poured in the culture dish of having sterilized, every ware 7-10 ml, culture medium thickness are 1.5 mm (sterile workings).
(B) switching experimental bacteria (being coated with bacterium) with microscale sampler get dilution good 10
8CFU/ml (1OD
660=10
8CFU/ml) bacteria suspension 0.1 ml of Hp spreads upon suitable culture dish surface equably.Be inverted in the 37oC drying baker and take out behind 15 min, purpose makes agar surface dry, for subsequent use.
(C) pasting the sample scraps of paper gets 6 μ l testing samples (mass concentration 2 mg/ml) with microscale sampler and injects on the round filter paper of having sterilized.The scraps of paper and the blank scraps of paper of contrast that contain sample with the aseptic nipper tweezer, by the sterile working respectively the scraps of paper be close to and contain the bacterio-agar surface, paste at a certain distance a piece of paper sheet.Every kind of bacterium is cooked 3 wares, and acquired results is asked its meansigma methods.
(D) cultivation places little aerobic bag with each plate, and gas generator is opened in sealing, places the 37oC incubator to cultivate 72h again.
(E) after the survey antibacterial circle diameter takes out flat board, measure respectively each scraps of paper size of antibacterial circle diameter on every side.With reference to the result of matched group, can draw the result of testing sample sensitive experiment.Triplicate.
II. agar dilution is measured MIC
(A) preparation of medicine flat board at first becomes the chemical compound of test the mother solution of 0.5 mg/ml with dimethyl sulfoxide (DMSO) solution preparation, with the sterilized water dilution, finally is made into 10.0 again, 8.0,6.0,4.5,4.0,3.5,3.0,2.5,2.0,1.5,1.0,0.5 with the concentration series of 0.25 μ g/ml, the concentration of DMSO in medium is less than 1%.The test compounds solution that 1 ml is prepared adds in addition 1 ml in the 9 ml Colombia culture medium of 50 ° of C and is incubated in the abundant mixing of the horse serum of 50 ° of C with being incubated, and casts to cool off in the culture dish.
(B) switching experimental bacteria (being coated with bacterium) with microscale sampler draw dilution good 1 * 10
8Bacteria suspension 0.1 ml of CFU/ml Hp spreads upon the culture dish surface equably, is inverted in the 37oC drying baker and takes out behind 15 min, and purpose makes agar surface dry, for subsequent use.
(C) determine that MIC (contains culture dish to be measured: 85% N at little aerobic bag
2, 10% CO
2With 5% O
2) in, insulation 37
oC cultivated 72 hours, observed the Hp growing state, contrasted with the blank group, take the sample least concentration that do not have bacteria growing fully as minimum inhibitory concentration (minimal inhibitory concentration, MIC) value.Positive control is ampicillin (Ampicillin).
3, the pharmacological results of Houttuynoid E
Experiment in vitro shows, Houttuynoid E has very strong anti Helicobacter pylori activity, and paper disk method shows that its antibacterial circle diameter is 19 mm (ATCC43504).Show that with agar dilution it can suppress the growth of 5 random clinical strains (Hp001, Hp003, Hp004, Hp018 and Hp036) and 1 reference culture (ATCC43504) fully, minimal inhibitory concentration (MIC) is 1.0 μ g/ml.Make positive control with the ampicillin, it is 2.0 μ g/ml to the Cmin (MIC) that 6 strains test bacterium suppresses fully.
Conclusion: it is strong that Houttuynoid E suppresses the energy force rate ampicillin of helicobacter pylori activity, explanation for the diseases such as the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer, Houttuynoid E is the chemical compound of a great exploitation potential for its.It can be directly used in the treatment of corresponding disease and the preparation of related drugs.
Claims (1)
1.Houttuynoid the application of E in Anti-helicobacter pylori drugs, described compound H outtuynoid E structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418406.2A CN102861067B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in preparing anti-helicobacter pylori (Hp) medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418406.2A CN102861067B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in preparing anti-helicobacter pylori (Hp) medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102861067A true CN102861067A (en) | 2013-01-09 |
| CN102861067B CN102861067B (en) | 2014-04-16 |
Family
ID=47440385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210418406.2A Active CN102861067B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in preparing anti-helicobacter pylori (Hp) medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861067B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101327266A (en) * | 2008-07-18 | 2008-12-24 | 南方医科大学 | Oral cavity nursing agent for preventing and treating oral disease induced by Helicobacter pylori infection contamination |
-
2012
- 2012-10-27 CN CN201210418406.2A patent/CN102861067B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101327266A (en) * | 2008-07-18 | 2008-12-24 | 南方医科大学 | Oral cavity nursing agent for preventing and treating oral disease induced by Helicobacter pylori infection contamination |
Non-Patent Citations (2)
| Title |
|---|
| SHAO-DAN CHEN ET AL: "Houttuynoids A-E, anti-herpes simplex virus active flavonoids with novel skeletons from houttuynia cordata", 《ORGANIC LETTERS》 * |
| 李爽 等: "鱼腥草的有效成分、药理作用及临床应用的研究进展", 《沈阳药科大学学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102861067B (en) | 2014-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988355A (en) | Application of Aphanamixoid A for preparing helicobacter pylori resistant medicine | |
| CN111419829B (en) | Application of honokiol in inhibiting streptococcus suis or biofilm thereof | |
| CN102872132B (en) | Application of Houttuynoid D in anti-helicobacter pylori drug | |
| CN102861055B (en) | Application of Houttuynoid A in helicobacter pylori resisting medicine | |
| CN102861067B (en) | Application of Houttuynoid E in preparing anti-helicobacter pylori (Hp) medicine | |
| CN102872154B (en) | Application of Houttuynoid B in helicobacter pylori resistant medicament | |
| CN102872131B (en) | Application of Houttuynoid C in preparing anti-helicobacter pylori drug | |
| CN103550204A (en) | Application of Neonectrolide A in preparation of anti-helicobacter pylori medicaments | |
| CN103356608A (en) | Application of Fluevirosines A in preparing anti-helicobacter pylori medicines | |
| CN103463023B (en) | Application of Lycojaponicumin B in helicobacter pylori resistant medicine | |
| CN103356600B (en) | Chukrasone B is preparing the application in Anti-helicobacter pylori drugs | |
| CN102885829A (en) | Application of Gypensapogenin B in helicobacter pylori resistant medicament | |
| CN103446127B (en) | Lycojaponicumin A is preparing the application in Anti-helicobacter pylori drugs | |
| CN102872028B (en) | Application of Gypensapogenin A in medicaments against helicobacter pylori | |
| CN103446085B (en) | Incarviatone A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103381165B (en) | Chukrasone A is preparing the application in Anti-helicobacter pylori drugs | |
| CN105535171A (en) | Rose tea | |
| CN103690527B (en) | Aphanamgrandiol A is preparing the application in Anti-helicobacter pylori drugs | |
| CN103120668A (en) | Application of Eryngiolide A in anti-helicobacter pylori drug | |
| CN103479646A (en) | Application of Kadcoccitones A to in preparation of anti-helicobacter pylori medicament | |
| CN103462979A (en) | Application of spirooliganones B in preparation of medicine inhibiting helicobacter pylori | |
| CN103356633A (en) | Use of Aspeverin in preparation of drug for resisting helicobacter pylori (Hp) | |
| CN103251639A (en) | Application of Polyflavanostilbene A in preparing anti-helicobacter pylori medicine | |
| CN103446152A (en) | Application of Lycojaponicumin C in anti-Helicobacter pylori drug | |
| CN103446117A (en) | Applications of Sarcaboside A in medicament against helicobacter pylori |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QIDONG TIANFEN ELECTRIC TOOL TECHNOLOGY INNOVATION Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141126 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226241 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141126 Address after: Qidong City, Jiangsu province 226241 Nantong lvsigang Tianfen electric tools trade city comprehensive building Patentee after: Qidong Tianfen Electric Tool Technology Innovation Center Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |